The Hospital will use SOPHiA GENETICS
technology to streamline workflows and expedite research
BOSTON and ROLLE, Switzerland, Dec. 21,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:
SOPH), a cloud-native software company and a leader in data-driven
medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™
Platform to help advance its research of Myeloid Disorders and
continue expanding the use of precision medicine for those in the
area. This latest implementation is an expansion of its existing
work with SOPHiA GENETICS.
For more than 50 years, patients suffering from
Myeloproliferative neoplasms (MPNs), a subset of myeloid
malignancies in which too many blood stem cells mature into red
blood cells, white blood cells, or platelets, have been referred to
the team at Hôpital Saint-Louis,
where the Cellular Biology Department is focused on in-depth
clinical research to help provide comprehensive care for MPN
patients. The implementation of the SOPHiA DDM™ Platform will help
the Cellular Biology Department expedite its research and increase
its ability to provide data-driven care to patients with MPN.
"While the providers and researchers in my department have
decades of experience with MPNs and are well-versed in providing
the highest quality care to our patients, we have been pleased with
the support of the innovative technology that SOPHiA GENETICS
offers," said Bruno Cassinat,
PharmD, Ph.D., Molecular Diagnostics, Hôpital Saint-Louis. "The SOPHiA DDM™ Platform has
been an essential tool to support us in streamlining our
bioinformatics workflows, expediting our research, and making
data-driven decisions for our patient population."
MPNs originate from hematopoietic disruptions in the myeloid
lineage. Advances in the study of MPNs depend on timely,
cost-effective, and reliable sequencing strategies. With the SOPHiA
DDM™ Platform, the Cellular Biology Department will provide its
patients with access to tailored next-generation sequencing
(NGS)-based workflows that enable accurate and sensitive
characterization of the complex mutational landscape associated
with myeloid neoplasms. These workflows will provide researchers
with high-quality, reproducible data on up-to-date gene panels to
expedite and advance research.
"As we continue expanding the use of data-driven medicine around
the world, we are keenly focused on aiding hospitals and labs with
their efforts to keep up with expanding international
recommendations and the near-constant progress being made in
targeted therapies for myeloid disorders," said Kevin Puylaert,
Managing Director, EMEA, SOPHiA GENETICS. "The SOPHiA DDM™ Platform
is designed to ensure our customers not only have access to NGS
workflows, but have the tools they need to identify insights that
will help guide research, accelerate studies, and inform
decision-making."
Molecular profiling via next-generation sequencing (NGS) is used
to best investigate the pathogenic variants causing different
myeloid malignancies, however, NGS produces a vast amount of
complex data. The SOPHiA DDM™ Platform is a NGS-based application
that uses artificial intelligence (AI) to efficiently analyze and
interpret raw NGS data for researchers. The Platform provides
streamlined insights in a matter of days, enabling clinicians to
more quickly make data-driven recommendations to their
patients.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on X,
LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook, and Instagram. Where
others see data, we see answers.
SOPHiA DDM™ Dx Myeloid Solution is
available as a CE-IVD product for In Vitro Diagnostic Use in
Europe and Turkey. The information in this press release
is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval
or market clearance by a governmental regulatory body for different
indications for use. Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hopital-saint-louis-implements-sophia-ddm-platform-to-further-research-of-myeloid-disorders-302020676.html
SOURCE SOPHiA GENETICS